Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodiesAlain P. Algazi, Ryan J. Sullivan, Zeynep Eroglu et al.|Cancer|2016Cited by 375
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C. Bendell, Michael Thomas, Helge Bischoff et al.|Investigational New Drugs|2019Cited by 30